Page 1 of Clinical Trials for ( Breast Neoplasms AND Male ), 443 Total Matches

  • …
  • Tell a FriendPrint
Next page of Clinical Trials »
  • 1
    Active, not recruiting
    Male Breast Cancer Summa Health System/Akron City Hospital Experience 1995-2007
    Last Updated: July 20, 2011
    Condition(s): Breast Cancer
  • 2
    Recruiting
    Study of Patients With Male Breast Cancer Treated Within the Past 20 Years
    Last Updated: January 8, 2011
    Condition(s): Breast Cancer
  • 3
    Completed
    Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer
    Last Updated: November 6, 2010
    Condition(s): Breast Cancer
  • 4
    Withdrawn
    Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer
    Last Updated: December 7, 2011
    Condition(s): Ductal Breast Carcinoma in Situ; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; HER2-positive Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Male Breast Cancer; Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate; Mucinous Ductal Breast Carcinoma; Papillary Ductal Breast Carcinoma; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Tubular Ductal Breast Carcinoma
  • 5
    Recruiting
    Vaccine Therapy in Combination With Ampligen® and/or Sargramostim in Patients With Stage II-IV HER2-Positive Breast Cancer
    Last Updated: January 3, 2012
    Condition(s): HER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
  • 6
    Recruiting
    Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
    Last Updated: January 17, 2012
    Condition(s): Male Breast Cancer; Recurrent Breast Cancer; Skin Metastases; Stage IV Breast Cancer
  • 7
    Recruiting
    Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
    Last Updated: January 5, 2012
    Condition(s): Estrogen Receptor-negative Breast Cancer; Hereditary Breast/Ovarian Cancer - BRCA1; Hereditary Breast/Ovarian Cancer - BRCA2; Male Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer
  • 8
    Completed
    Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer
    Last Updated: May 29, 2009
    Condition(s): Breast Cancer; Breast Neoplasms, Male; Carcinoma, Ductal
  • 9
    Active, not recruiting
    ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
    Last Updated: June 7, 2011
    Condition(s): Male Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
  • 10
    Completed
    Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
    Last Updated: July 8, 2011
    Condition(s): Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Inflammatory Breast Cancer; Male Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage IIIB Breast Cancer; Stage IV Breast Cancer
  • 11
    Recruiting
    Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
    Last Updated: March 26, 2012
    Condition(s): Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Primary Hepatocellular Carcinoma; Chondrosarcoma; Clear Cell Sarcoma of the Kidney; Conjunctival Kaposi Sarcoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Hormone-resistant Prostate Cancer; Limited Stage Small Cell Lung Cancer; Localized Resectable Adult Primary Liver Cancer; Male Breast Cancer; Mast Cell Sarcoma; Ovarian Sarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Primary Liver Cancer; Recurrent Adult Soft Tissue Sarcoma; Recurrent Bladder Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Esophageal Cancer; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Gastric Cancer; Recurrent Kaposi Sarcoma; Recurrent Melanoma; Recurrent Non-small Cell Lung Cancer; Recurrent Osteosarcoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Prostate Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Small Cell Lung Cancer; Recurrent Uterine Sarcoma; Small Intestine Leiomyosarcoma; Stage I Colon Cancer; Stage I Rectal Cancer; Stage I Uterine Sarcoma; Stage IA Breast Cancer; Stage IA Gastric Cancer; Stage IA Ovarian Epithelial Cancer; Stage IA Ovarian Germ Cell Tumor; Stage IB Breast Cancer; Stage IB Gastric Cancer; Stage IB Ovarian Epithelial Cancer; Stage IB Ovarian Germ Cell Tumor; Stage IC Ovarian Epithelial Cancer; Stage IC Ovarian Germ Cell Tumor; Stage II Breast Cancer; Stage II Uterine Sarcoma; Stage IIA Colon Cancer; Stage IIA Gastric Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Ovarian Germ Cell Tumor; Stage IIA Rectal Cancer; Stage IIB Colon Cancer; Stage IIB Esophageal Cancer; Stage IIB Gastric Cancer; Stage IIB Melanoma; Stage IIB Non-small Cell Lung Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Ovarian Germ Cell Tumor; Stage IIB Rectal Cancer; Stage IIC Colon Cancer; Stage IIC Melanoma; Stage IIC Ovarian Epithelial Cancer; Stage IIC Ovarian Germ Cell Tumor; Stage IIC Rectal Cancer; Stage III Uterine Sarcoma; Stage IIIA Breast Cancer; Stage IIIA Colon Cancer; Stage IIIA Esophageal Cancer; Stage IIIA Gastric Cancer; Stage IIIA Melanoma; Stage IIIA Non-small Cell Lung Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Ovarian Germ Cell Tumor; Stage IIIA Rectal Cancer; Stage IIIB Breast Cancer; Stage IIIB Colon Cancer; Stage IIIB Esophageal Cancer; Stage IIIB Gastric Cancer; Stage IIIB Melanoma; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Ovarian Germ Cell Tumor; Stage IIIB Rectal Cancer; Stage IIIC Breast Cancer; Stage IIIC Colon Cancer; Stage IIIC Esophageal Cancer; Stage IIIC Gastric Cancer; Stage IIIC Melanoma; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Ovarian Germ Cell Tumor; Stage IIIC Rectal Cancer; Stage IV Bladder Cancer; Stage IV Esophageal Cancer; Stage IV Gastric Cancer; Stage IV Melanoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Uterine Sarcoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer; Unspecified Adult Solid Tumor, Protocol Specific
  • 12
    Recruiting
    PD 0332991 in Treating Patients With Refractory Solid Tumors
    Last Updated: February 7, 2012
    Condition(s): Adult Solid Tumor; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Adult Central Nervous System Germ Cell Tumor; Adult Teratoma; Benign Teratoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Familial Testicular Germ Cell Tumor; HER2-negative Breast Cancer; HER2-positive Breast Cancer; Male Breast Cancer; Ovarian Immature Teratoma; Ovarian Mature Teratoma; Ovarian Monodermal and Highly Specialized Teratoma; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell Tumor; Recurrent Extragonadal Seminoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Melanoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Rectal Cancer; Stage III Extragonadal Non-seminomatous Germ Cell Tumor; Stage III Extragonadal Seminoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Ovarian Germ Cell Tumor; Stage IV Breast Cancer; Stage IV Colon Cancer; Stage IV Extragonadal Non-seminomatous Germ Cell Tumor; Stage IV Extragonadal Seminoma; Stage IV Melanoma; Stage IV Ovarian Germ Cell Tumor; Stage IV Rectal Cancer; Testicular Immature Teratoma; Testicular Mature Teratoma
  • 13
    Terminated
    Endoscopic Breast Surgery in Treating Patients With Breast Cancer
    Last Updated: March 10, 2012
    Condition(s): Male Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
  • 14
    Active, not recruiting
    Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
    Last Updated: March 5, 2012
    Condition(s): Extensive Stage Small Cell Lung Cancer; Hereditary Paraganglioma; Male Breast Cancer; Malignant Paraganglioma; Metastatic Gastrointestinal Carcinoid Tumor; Metastatic Pheochromocytoma; Pancreatic Polypeptide Tumor; Recurrent Breast Cancer; Recurrent Cervical Cancer; Recurrent Endometrial Carcinoma; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Recurrent Neuroendocrine Carcinoma of the Skin; Recurrent Non-small Cell Lung Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Pheochromocytoma; Recurrent Prostate Cancer; Recurrent Renal Cell Cancer; Recurrent Small Cell Lung Cancer; Recurrent Uterine Sarcoma; Regional Gastrointestinal Carcinoid Tumor; Regional Pheochromocytoma; Stage III Cervical Cancer; Stage III Endometrial Carcinoma; Stage III Neuroendocrine Carcinoma of the Skin; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Prostate Cancer; Stage III Renal Cell Cancer; Stage III Uterine Sarcoma; Stage IIIA Breast Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Breast Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Endometrial Carcinoma; Stage IV Neuroendocrine Carcinoma of the Skin; Stage IV Non-small Cell Lung Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Uterine Sarcoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer; Thyroid Gland Medullary Carcinoma
  • 15
    Terminated
    Pazopanib Hydrochloride and Anastrozole Before Surgery in Treating Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
    Last Updated: May 7, 2012
    Condition(s): Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer
  • 16
    Recruiting
    Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer
    Last Updated: May 4, 2012
    Condition(s): HER2-negative Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
  • 17
    Recruiting
    Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer
    Last Updated: December 14, 2011
    Condition(s): Male Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
  • 18
    Recruiting
    Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
    Last Updated: February 13, 2012
    Condition(s): Inflammatory Breast Cancer; Male Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
  • 19
    Recruiting
    Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
    Last Updated: May 17, 2012
    Condition(s): Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Male Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer
  • 20
    Not yet recruiting
    Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer
    Last Updated: May 11, 2012
    Condition(s): HER2-positive Breast Cancer; Male Breast Cancer; Stage IV Breast Cancer
Next page of Clinical Trials »
  • …
  • Tell a FriendPrint

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=Breast+Neoplasms%2C+Male